Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Expected to Announce Earnings of -$0.16 Per Share

Brokerages expect Oncternal Therapeutics, Inc. (NASDAQ:ONCT) to report earnings of ($0.16) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Oncternal Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.13). Oncternal Therapeutics posted earnings per share of ($0.22) during the same quarter last year, which would indicate a positive year over year growth rate of 27.3%. The company is scheduled to report its next earnings report on Wednesday, November 3rd.

On average, analysts expect that Oncternal Therapeutics will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.71) to ($0.51). For the next fiscal year, analysts expect that the company will report earnings of ($0.84) per share, with EPS estimates ranging from ($1.05) to ($0.67). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow Oncternal Therapeutics.

Oncternal Therapeutics (NASDAQ:ONCT) last announced its earnings results on Thursday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $0.88 million for the quarter, compared to analyst estimates of $1.09 million. Oncternal Therapeutics had a negative return on equity of 24.25% and a negative net margin of 541.09%.

Separately, Zacks Investment Research raised shares of Oncternal Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 21st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $14.33.

Institutional investors have recently added to or reduced their stakes in the company. UBS Group AG acquired a new stake in Oncternal Therapeutics in the first quarter worth about $27,000. NinePointTwo Capital acquired a new stake in Oncternal Therapeutics in the 2nd quarter valued at about $49,000. ProShare Advisors LLC acquired a new stake in Oncternal Therapeutics in the 2nd quarter valued at about $55,000. Citigroup Inc. acquired a new stake in Oncternal Therapeutics in the 1st quarter valued at about $67,000. Finally, SG Americas Securities LLC purchased a new stake in Oncternal Therapeutics during the second quarter valued at about $73,000. Institutional investors and hedge funds own 26.76% of the company’s stock.

Oncternal Therapeutics stock traded up $0.05 during trading on Wednesday, reaching $4.15. The company had a trading volume of 7,614 shares, compared to its average volume of 1,260,539. Oncternal Therapeutics has a 12-month low of $1.49 and a 12-month high of $10.56. The stock’s 50 day moving average price is $4.09 and its two-hundred day moving average price is $5.49. The firm has a market capitalization of $204.95 million, a price-to-earnings ratio of -6.95 and a beta of 1.76.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Cirmtuzumab, TK216, and ROR1 CAR-T. The company was founded by David F. Hale and James B. Breitmeyer in 1997 and is headquartered in San Diego, CA.

See Also: Options Trading

Get a free copy of the Zacks research report on Oncternal Therapeutics (ONCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.